Figure 1
Schematic representation of the induction and consolidation courses employed for treating patients enrolled in the AIEOP AML 2002/01 trial. AVE, HD Ara-C and etoposide; CONS, consolidation; HAM, HD Ara-C and mitoxantrone; MFD, matched family donor.

Schematic representation of the induction and consolidation courses employed for treating patients enrolled in the AIEOP AML 2002/01 trial. AVE, HD Ara-C and etoposide; CONS, consolidation; HAM, HD Ara-C and mitoxantrone; MFD, matched family donor.

Close Modal

or Create an Account

Close Modal
Close Modal